Literature DB >> 2434660

Effects of trimetazidine on action potentials and membrane currents of guinea-pig ventricular myocytes.

T Kiyosue, S Nakamura, M Arita.   

Abstract

The effects of trimetazidine on membrane potentials and membrane currents of enzymatically isolated guinea-pig ventricular cells were studied with the use of giga-seal suction pipettes for patch clamp. Trimetazidine (3 X 10(-5) M) decreased the action potential duration from 433 +/- 179 ms (mean and S.D., n = 9) to 319 +/- 156 ms within 8 mins. In voltage clamp experiment, trimetazidine at a concentration of 1.5 X 10(-4) M decreased the peak amplitude of calcium current by 40% (0.92 +/- 0.46 nA to 0.55 +/- 0.19 nA, mean +/- S.D., n = 5). The effect on calcium current was rate-dependent, e.g., at 1 Hz, trimetazidine blocked a larger fraction of the calcium current than at 0.2 Hz. The drug decreased the conductance of potassium current which flows via inward rectifier potassium channel from 28 +/- 11 nS to 19 +/- 10 nS, n = 5, P less than 0.05). Trimetazidine shifted the steady state current-voltage relationship outward at potentials positive to -20 mV. This shift was not due to the enhanced time- and voltage-dependent outward current (Ik). From these findings, it was concluded that trimetazidine shortens action potential duration by blocking the calcium channels with increases in steady state outward current or a possible blockade of non-inactivated component of the calcium current, at the plateau potentials. The reduction of calcium current and of inward rectifier potassium current may protect the cardiac cells from accumulation of calcium ions and from loss of potassium ions, in the presence of ischemia.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2434660     DOI: 10.1016/s0022-2828(86)80433-3

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  9 in total

Review 1.  Targeting myocardial substrate metabolism in heart failure: potential for new therapies.

Authors:  Hossein Ardehali; Hani N Sabbah; Michael A Burke; Satyam Sarma; Peter P Liu; John G F Cleland; Aldo Maggioni; Gregg C Fonarow; E Dale Abel; Umberto Campia; Mihai Gheorghiade
Journal:  Eur J Heart Fail       Date:  2012-02       Impact factor: 15.534

Review 2.  Trimetazidine. A review of its use in stable angina pectoris and other coronary conditions.

Authors:  K J McClellan; G L Plosker
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

3.  Effects of AN-132, a novel antiarrhythmic lidocaine analogue, and of lidocaine on membrane ionic currents of guinea-pig ventricular myocytes.

Authors:  K Ono; T Kiyosue; M Arita
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989 Jan-Feb       Impact factor: 3.000

4.  Effects of trimetazidine on in vivo coronary arterial platelet thrombosis.

Authors:  P R Belcher; A J Drake-Holland; J W Hynd; M I Noble
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

5.  Internal pH, Na+, and Ca2+ regulation by trimetazidine during cardiac cell acidosis.

Authors:  J F Renaud
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

6.  Evolution of free radical formation during low-flow ischemia and reperfusion in isolated rat heart.

Authors:  V Maupoil; L Rochette; A Tabard; P Clauser; C Harpey
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

7.  Effects of cibenzoline, a new class Ia antiarrhythmic drug, on various membrane ionic currents and action potentials of guinea-pig ventricular cells.

Authors:  T Sato; B Wu; T Kiyosue; M Arita
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-08       Impact factor: 3.000

Review 8.  Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease.

Authors:  Piotr Chrusciel; Jacek Rysz; Maciej Banach
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

Review 9.  Changes in Myocardial Metabolism Preceding Sudden Cardiac Death.

Authors:  J Snyder; R Zhai; A I Lackey; P Y Sato
Journal:  Front Physiol       Date:  2020-06-16       Impact factor: 4.566

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.